NH Nonghyup Life Launches 'Happiness Double NH Integrated Cancer Insurance'

Comprehensive Coverage from Small-Amount Cancer to 9 Major High-Cost Cancers
Comprehensive Protection through Special Contracts Including Diagnosis and Treatment Before Cancer Onset

[Asia Economy Reporter Ki Ha-young] NH Nonghyup Life announced on the 1st that it has launched the 'Happy Double NH Integrated Cancer Insurance (renewable, non-renewable, no-renewal)' which comprehensively covers diagnosis and treatment from before cancer onset.

This product guarantees general cancer diagnosis expenses as the main contract, and pays insurance benefits when diagnosed with minor cancer through the 'Minor Cancer Diagnosis Special Contract (renewable, non-renewable, no-renewal)'. If subscribed to the '9 Major High-Cost Cancer Diagnosis Special Contract (renewable, no-renewal)', additional diagnosis benefits are paid for the 9 major high-cost cancers including brain, lung, pancreas, and esophagus.

By subscribing to the 'Re-diagnosis Cancer Coverage Special Contract (renewable, no-renewal)', customers can also reduce worries about cancer recurrence. If cancer (excluding prostate cancer, other skin cancers, thyroid cancer, and colorectal mucosal cancer) is re-diagnosed after 2 years from the initial diagnosis, additional insurance benefits are paid. Also, if the cancer is not cured, cancer diagnosis benefits can be continuously received every 2 years until complete recovery.

This product newly established coverage special contracts for pre-cancer onset as well as cancer diagnosis expenses. The 'Specific Benign Neoplasm Diagnosis Special Contract (renewable, no-renewal)' and 'Hyperthyroidism Treatment Special Contract (renewable, no-renewal)' cover premonitory symptoms before cancer onset, including removal of stomach and colon polyps and treatment of hyperthyroidism. Additionally, when prostate and thyroid biopsy tissue pathology diagnosis is performed by extracting some cells and tissues using a needle, coverage is provided through the 'Prostate Needle Biopsy Tissue Pathology Diagnosis Special Contract (renewable, no-renewal)' and 'Thyroid Needle Biopsy Tissue Pathology Diagnosis Special Contract (renewable, no-renewal)'.

To allow patients to focus on treatment after cancer onset, treatment expenses for hospitalization, surgery, and chemotherapy are also covered. The product includes coverage special contracts for new medical technology treatments such as 'Targeted Anticancer Drug Approved Treatment', which minimizes damage to normal cells, and 'Specific Anticancer Hormone Drug Approved Treatment', which blocks and reduces hormones to inhibit cancer cell growth and spread, slowing progression.

There are renewable and non-renewable types depending on renewal status, allowing selection according to individual financial situations. According to subscription type, it is divided into general subscription and simplified subscription, enabling those with pre-existing conditions such as hypertension and diabetes to subscribe through the simplified subscription. Subscription is possible if there are no applicable cases for the following three items: ▲doctor's opinion required for hospitalization, surgery, or additional tests within 3 months ▲hospitalization or surgery (including cesarean section) within 2 years ▲diagnosis, hospitalization, or surgery for cancer within 5 years.

For the general subscription type, coverage special contracts for the three major diseases?cerebrovascular disease and ischemic heart disease?are added to expand customer choices beyond cancer.

The subscription age ranges from a minimum of 15 to a maximum of 80 years old. The insurance premium for the main contract subscription amount of 25 million KRW, Type 2 (general subscription type), is 20,750 KRW for men and 26,250 KRW for women for the renewable type (15-year maturity, electric payment), and 89,500 KRW for men and 68,750 KRW for women for the non-renewable type (90-year maturity, 20-year payment).

CEO Kim In-tae said, "This new product expands coverage to guarantee the high-cost new medical technology treatment expenses caused by cancer onset so that customers can focus on cancer treatment," and added, "We will continue to provide products that can reliably support our customers."

This content was produced with the assistance of AI translation services.